D-Wave Quantum: A 91.90% Cancer Result, a ¥40 Million Customer Prize and the November Print That Will Grade Both

D-Wave Quantum finds itself caught between two very different kinds of news. On the operational side, the quantum computing specialist is pushing out research and partnerships at a steady clip. On the market side, its shares have been dragged lower by forces that have little to do with its own business — and by a lawsuit that has plenty to do with it.

The stock posted a daily move of -5.7%, extending a weekly decline that media reports largely attributed to a broader technology selloff triggered by disappointing results from Intel and Amazon. A separate reading put the most recent daily change at -3.9%, with quantum computing names already under pressure on the Friday as Intel's figures and outlook weighed on the wider sector. Either way, the takeaway is the same: sentiment toward tech, not a verdict on D-Wave's technology, drove much of the slide.

That distinction matters, and it cuts both ways. A sector-wide retreat says nothing definitive about D-Wave's business, and a falling share price on its own does not prove that its technological progress has stalled. But it would be just as lazy to pin every risk on the selloff. On Thursday, Pomerantz disclosed that a securities class action had been filed against D-Wave and certain executives, alleging misleading statements. Those are allegations, not court-established facts — a distinction investors should hold onto rather than treat the complaint as either a proven offense or an inconvenience to be ignored.

Research Wins, and What They Don't Prove

The company's scientific output has been genuine. A study led by Florida Atlantic University examined lung cancer prediction using limited data, with D-Wave's annealing quantum computers doing the heavy lifting. The method reached 94.31% accuracy in simulation and 91.90% on quantum hardware.

Those numbers are eye-catching, and the fact that the work ran on actual quantum hardware gives the announcement real weight for assessing the technology. Yet a research application and a commercially viable product are measured on different scales. D-Wave itself flags that the experimental dataset included synthetic examples rather than newly collected patient data. That caveat belongs at the center of any assessment, not in a footnote: the reported accuracy is a study result, not evidence of performance in patient care. Investors who turn a high hit rate into a revenue forecast are skipping the step that matters most.

The same logic applies to the customer front. On October 28, D-Wave reported that client Shionogi & Co. took first place in the NEDO Challenge's quality-of-life category, recognized for drug discovery research using quantum computers. The award carried a prize of ¥40 million. It is a positive signal for practical experimentation — but it honors the customer and its research, which argues for the relevance of the applications rather than for D-Wave's own commercial strength.

Roughly a week earlier, the company signed a letter of intent with LG CNS to advance quantum computing for operational optimization in South Korea and international markets, with planned applications spanning manufacturing, telecommunications, financial services and retail. The breadth of those use cases opens up possibilities, but the agreement is explicitly non-binding. It documents shared intent, not a firm order. Reading secured business into it skips the transition from a possible application to economically durable results.

The Number That Outranks the Headlines

All of this sets up a single date. D-Wave has scheduled its third-quarter 2026 results for November 10, before the market opens — the next concrete test of how the business actually stands.

Reports from October 26 suggest investors have been focused on the gap between order intake growth and its conversion into revenue. That is exactly where the next assessment should anchor: not in new use cases, but in their translation into sales. A growing order book can support expectations, yet it is not the same as realized revenue. The relevant question for the upcoming figures is whether they make that economic link clearer. The latest research announcement does not answer it.

Weighing it all, a cautious stance seems right. The technology selloff explains a substantial part of the recent weakness without erasing either the legal uncertainty or the need for commercial proof. D-Wave has interesting application signals to show. Turning them into credible business results is the step the November print — not another accuracy figure — will have to deliver.